Long-Term Outcomes in IgA Nephropathy

被引:131
|
作者
Pitcher, David [1 ,2 ]
Braddon, Fiona [1 ]
Hendry, Bruce [3 ]
Mercer, Alex [4 ]
Osmaston, Kate [1 ]
Saleem, Moin A. A. [5 ,6 ]
Steenkamp, Retha [1 ]
Wong, Katie [1 ,2 ]
Turner, A. Neil [7 ]
Wang, Kaijun [3 ]
Gale, Daniel P. P. [2 ]
Barratt, Jonathan [8 ,9 ,10 ]
机构
[1] UK Kidney Assoc, UK Renal Registry, Bristol, England
[2] UCL, Dept Renal Med, London, England
[3] Travere Therapeut Inc, San Diego, CA USA
[4] JAMCO Pharm Consulting, Stockholm, Sweden
[5] Univ Bristol, Bristol, England
[6] Bristol Royal Hosp Children, Bristol, England
[7] Univ Edinburgh, Edinburgh, Scotland
[8] Univ Leicester, Leicester, England
[9] Leicester Gen Hosp, Leicester, England
[10] Univ Leicester, Dept Cardiovasc Sci, Univ Rd, Leicester LE1 7RH, England
关键词
chronic kidney disease; chronic kidney failure; end-stage kidney disease (ESKD); end-stage renal disease (ESRD); IGA nephropathy; kidney disease; nephropathy; proteinuria; CHRONIC KIDNEY-DISEASE; URINE PROTEIN; ASSOCIATION; ALBUMINURIA; REMISSION; FAILURE; RISK;
D O I
10.2215/CJN.0000000000000135
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background IgA nephropathy can progress to kidney failure, and risk assessment soon after diagnosis has advantages both for clinical management and the development of new therapeutics. We present relationships among proteinuria, eGFR slope, and lifetime risks for kidney failure. Methods The IgA nephropathy cohort (2299 adults and 140 children) of the UK National Registry of Rare Kidney Diseases (RaDaR) was analyzed. Patients enrolled had a biopsy-proven diagnosis of IgA nephropathy plus proteinuria >0.5 g/d or eGFR <60 ml/min per 1.73 m(2). Incident and prevalent populations and a population representative of a typical phase 3 clinical trial cohort were studied. Analyses of kidney survival were conducted using Kaplan-Meier and Cox regression. eGFR slope was estimated using linear mixed models with random intercept and slope. Results The median (Q1, Q3) follow-up was 5.9 (3.0, 10.5) years; 50% of patients reached kidney failure or died in the study period. The median (95% confidence interval [CI]) kidney survival was 11.4 (10.5 to 12.5) years; the mean age at kidney failure/death was 48 years, and most patients progressed to kidney failure within 10-15 years. On the basis of eGFR and age at diagnosis, almost all patients were at risk of progression to kidney failure within their expected lifetime unless a rate of eGFR loss <= 1 ml/min per 1.73 m(2) per year was maintained. Time-averaged proteinuria was significantly associated with worse kidney survival and more rapid eGFR loss in incident, prevalent, and clinical trial populations. Thirty percent of patients with time-averaged proteinuria of 0.44 to <0.88 g/g and approximately 20% of patients with time-averaged proteinuria <0.44 g/g developed kidney failure within 10 years. In the clinical trial population, each 10% decrease in time-averaged proteinuria from baseline was associated with a hazard ratio (95% CI) for kidney failure/death of 0.89 (0.87 to 0.92). Conclusions Outcomes in this large IgA nephropathy cohort are generally poor with few patients expected to avoid kidney failure in their lifetime. Significantly, patients traditionally regarded as being low risk, with proteinuria <0.88 g/g (<100 mg/mmol), had high rates of kidney failure within 10 years.
引用
收藏
页码:727 / 738
页数:12
相关论文
共 50 条
  • [21] LONG-TERM GRAFT OUTCOMES OF POST TRANSPLANT IGA NEPHROPATHY IN LIVE DONOR RENAL TRANSPLANTATION
    Prasad, Narayan
    Khurana, Mudit
    Gupta, Amit
    Kaul, Anupma
    Bhadouria, D. S.
    Patel, M. R.
    Behera, M. R.
    Yachcha, Monika
    Kushwaha, R. S.
    TRANSPLANTATION, 2020, 104 (09) : S412 - S412
  • [22] Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria
    Jia, Qing
    Ma, Feng
    Yang, Xiaoxia
    Li, Linlin
    Liu, Chunmei
    Sun, Ruiling
    Li, Rong
    Sun, Shiren
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (03) : 257 - 265
  • [23] Long-term outcome of childhood IgA nephropathy with minimal proteinuria
    Asumi Higa
    Yuko Shima
    Taketsugu Hama
    Masashi Sato
    Hironobu Mukaiyama
    Hiroko Togawa
    Ryojiro Tanaka
    Kandai Nozu
    Mayumi Sako
    Kazumoto Iijima
    Koichi Nakanishi
    Norishige Yoshikawa
    Pediatric Nephrology, 2015, 30 : 2121 - 2127
  • [24] Long-term efficacy of tonsillectomy in chinese patients with IgA nephropathy
    Chen, Yu
    Tang, Zheng
    Wang, Qingwen
    Yu, Yusheng
    Zeng, Caihong
    Chen, Huiping
    Liu, Zhi-hong
    Li, Lei-shi
    AMERICAN JOURNAL OF NEPHROLOGY, 2007, 27 (02) : 170 - 175
  • [25] Long-term study of mycophenolate mofetil treatment in IgA nephropathy
    Tang, Sydney C. W.
    Tang, Anthony W. C.
    Wong, Sunny S. H.
    Leung, Joseph C. K.
    Ho, Yiu Wing
    Lai, Kar Neng
    KIDNEY INTERNATIONAL, 2010, 77 (06) : 543 - 549
  • [27] PHENYTOIN IN THE TREATMENT OF IGA NEPHROPATHY - RESULTS OF A LONG-TERM STUDY
    EGIDO, J
    RIVERA, F
    SANCHO, J
    HERNANDO, L
    KIDNEY INTERNATIONAL, 1984, 26 (02) : 223 - 223
  • [28] IGA NEPHROPATHY - LONG-TERM PROGNOSIS FOR PEDIATRIC-PATIENTS
    WYATT, RJ
    KRITCHEVSKY, SB
    WOODFORD, SY
    MILLER, PM
    ROY, S
    HOLLAND, NH
    JACKSON, E
    BISHOF, NA
    JOURNAL OF PEDIATRICS, 1995, 127 (06): : 913 - 919
  • [29] Long-term treatment of IgA nephropathy with cyclosporin A - a preliminary report
    Chabova, V
    Tesar, V
    Zabka, J
    Rychlik, I
    Merta, M
    Jirsa, M
    Stejskalova, A
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (10) : 2206 - 2207
  • [30] CLINICAL PRESENTATION OF IGA NEPHROPATHY AND LONG-TERM RENAL OUTCOME
    Stefan, Gabriel
    Stancu, Simona
    Zugravu, Adrian Dorin
    Petre, Nicoleta
    Mircescu, Gabriel
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36